The Lancet on the anti-IL-5 antibody mepolizumab in individuals with allergic asthma, evidence has accumulated that the pathogenetic role of eosinophils is fundamentally different between asthma ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. Regeneron ...

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers hope. Click for my GILD and KYMR update.

The biotech will work on molecular glue degraders with Gilead in a new deal. Existing partner Sanofi changed its focus to a ...

Sanofi SNY announced that the FDA has granted orphan drug designation to its investigational drug, riliprubart, for the treatment of antibody-mediated rejection (AMR) in solid organ transplantation.

Credit: Toa55/Shutterstock. The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for adults with bullous pemphigoid (BP), a ...

Alyssa Johnsen, MD, PhD, Global Therapeutic Area Head, Immunology and Oncology Development, Sanofi said, “Until now, treating bullous pemphigoid was very challenging for elderly patients struggling ...

18.3% of patients on Dupixent achieved sustained remission vs. 6.1% on placebo at 36 weeks. Median corticosteroid use was 2.8g with Dupixent vs. 4.1g with placebo in BP patients. From tariffs to ...